
## Yuanyun Xie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10783787/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain, 2008, 132, 919-932.	7.6	135
2	Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Human Molecular Genetics, 2012, 21, 2219-2232.	2.9	122
3	In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides. Molecular Therapy, 2014, 22, 2093-2106.	8.2	115
4	Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Human Molecular Genetics, 2010, 19, 1528-1538.	2.9	100
5	A fully humanized transgenic mouse model of Huntington disease. Human Molecular Genetics, 2013, 22, 18-34.	2.9	93
6	Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease. Neurobiology of Disease, 2011, 41, 249-260.	4.4	92
7	Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease. Science Translational Medicine, 2018, 10, .	12.4	89
8	An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. Human Molecular Genetics, 2016, 25, 3654-3675.	2.9	85
9	Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Scientific Reports, 2015, 5, 12166.	3.3	82
10	Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiology of Disease, 2015, 76, 46-56.	4.4	78
11	Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. Human Molecular Genetics, 2012, 21, 1954-1967.	2.9	67
12	Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease. Human Molecular Genetics, 2016, 25, ddw122.	2.9	62
13	NPO3, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiology of Disease, 2012, 48, 282-289.	4.4	47
14	Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. Nucleic Acids Research, 2019, 48, 36-54.	14.5	41
15	A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. Human Molecular Genetics, 2017, 26, ddx021.	2.9	37
16	Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease. Journal of Neuroscience, 2021, 41, 780-796.	3.6	37
17	HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo. Human Molecular Genetics, 2018, 27, 239-253.	2.9	21
18	The Interaction of Aging and Cellular Stress Contributes to Pathogenesis in Mouse and Human Huntington Disease Neurons. Frontiers in Aging Neuroscience, 2020, 12, 524369.	3.4	21

YUANYUN XIE

#	Article	IF	CITATIONS
19	Potential roles of Alzheimer precursor protein A4 and ?-amyloid in survival and function of aged spinal motor neurons after axonal injury. Journal of Neuroscience Research, 2003, 73, 557-564.	2.9	19
20	Expression and Role of Low-Affinity Nerve Growth Factor Receptor (p75) in Spinal Motor Neurons of Aged Rats following Axonal Injury. Developmental Neuroscience, 2003, 25, 65-71.	2.0	14
21	Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice. Neurobiology of Disease, 2022, 166, 105652.	4.4	12